NOTICE OF LIMITED COMPETITION FOR COMPETING SUPPLEMENTAL APPLICATIONS TO DISSEMINATE PROMISING CANCER CONTROL INTERVENTIONS TESTED IN EFFECTIVE RESEARCH PROJECTS Release Date: May 9, 2001 NOTICE: NOT-CA-01-010 National Cancer Institute The National Cancer Institute’s (NCI) Division of Cancer Control and Population Sciences (DCCPS) announces a limited competition for competing supplemental applications to NCI-funded research projects supported by R01, P01, P50, U01 and U19 grant mechanisms. Most researchers who propose to develop and test cancer control interventions either explicitly or implicitly intend to disseminate the interventions within the populations from which the sample is drawn if the interventions prove efficacious. However, without financial support for the costs of dissemination, active dissemination rarely occurs. The purpose of these supplements is to fund the dissemination of promising interventions where statistical significance and potential public health/clinical significance of intervention effects strongly suggest the merits of dissemination to the broader population from which the intervention sample was drawn. The supplement may also support cost-effectiveness evaluations of interventions, qualitative and quantitative research needed to adapt intervention products for use after formal research evaluation has ended and dissemination of intervention products. These supplements have been designed to provide one-year funding (with the possibility of a second year of supplemental funding) to cancer control investigators whose intervention efficacy data have been analyzed, who are in the final years of their R01, P01, P50, U01 or U19 awards. Research results should show statistical significance and public health/clinical significance of intervention effects and thus provide the rationale for dissemination to the broader population from which the intervention sample was originally drawn. Intervention research across the cancer control continuum, that may be eligible for these supplements, includes: tobacco use prevention and cessation, promotion of appropriate changes in diet and physical activity, reduction of sun exposure and UV radiation exposure, facilitating informed decisions about genetic testing for cancer susceptibility, enhancing screening for breast, cervix and colorectal cancers, and improving coping skills and quality of life for cancer survivors and their families. Requests for competing supplements under this program should be developed using standard forms and format of the PHS 398 (revised 4/98). All sections of the PHS 398 package should be completed. Also include the following with the PHS 398: A. Cover letter requesting the competing supplement and identifying this program B. Face page C. Budget and budget justification D. Biosketches and other support for participating investigators E. Description of the proposed dissemination plan, including an introduction, intervention efficacy data justifying dissemination, relevance to target populations and settings for dissemination, proposed dissemination theory and methodology, procedures to assess dissemination program effectiveness, and plans to sustain effective dissemination approaches beyond the supplement funding period (not to exceed 12 pages), F. Intervention products (or copies) should be provided G. Relevant letters of support from key partners should be included. Requests should contain enough detail to allow assessment of the scientific merit of the proposed dissemination plans and the appropriateness of the request for supplemental funding. Budgets may not exceed $100,000 in direct costs for a time period not exceeding 12 months. If there are extenuating circumstances that require a larger budget, these should be documented and justified. If this initiative is reissued, a second one-year administrative supplement may be requested to complete the dissemination work initiated in the first supplement year. Funding of the subsequent administrative supplement will depend on an administrative review of the first year’s progress report and availability of funds. All requests require an itemized budget and must be countersigned by the grantee institution’s business office. Requests for supplements under this program must comply with NIH policies for inclusion of women, minorities, and children in research involving human subjects. Submissions may be made to this supplement no earlier than 24 months and no later than six months prior to the end of the last year of a currently funded NCI intervention research R01, P01, P50, U01 or U19 and no later than August 16, 2001. Investigators planning the submission of a competing continuation application (Type 2) of their R01, P01, P50, U01 or U19 intervention research award may submit the supplement application after, and if, the award notice of the Type 2 application has been made, and if the Type 2 application does not include funding for the dissemination effort. In this case, the supplement (if awarded) will be linked to the Type 2 award to disseminate the evidence- based intervention tested in the original R01, P01, P50, U01 or U19 (Type 1) project. Requests will undergo review for scientific merit by extramural reviewers with expertise in the cancer control intervention area and/or in dissemination and diffusion research. Awards will be determined on the basis of scientific merit, program relevance, dissemination potential, and availability of funds. Special consideration will be given to applications that plan to disseminate interventions tested in low income and ethnically diverse populations. The earliest anticipated award date for this program will be March 1, 2002. Inquiries related to this notice should be addressed to the NCI Program Director for the particular R01, P01, P50, U01 or U19 for which the supplement is being requested. Applicants are STRONGLY ENCOURAGED to discuss the efficacy data (e.g. effect sizes, consistency with prior research, relevance to target populations) supporting their competing supplement request from the original project with their respective NCI research project Program Director prior to submission. INQUIRIES Requests should be sent to: Jon F. Kerner, Ph.D. Assistant Deputy Director for Research Dissemination and Diffusion Division of Cancer Control and Populations Sciences 6130 Executive Boulevard Executive Plaza North, Room 6144 Rockville, MD 20852 Direct inquiries regarding fiscal matters should be made to: Ms. Crystal Wolfrey Grants Administration Branch 6120 Executive Boulevard Executive Plaza South, Room 243 Rockville, MD 20852

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy
NIH... Turning Discovery Into Health®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.